DE60006250D1 - Formulierung zur verzögerten freisetzung von peptiden - Google Patents
Formulierung zur verzögerten freisetzung von peptidenInfo
- Publication number
- DE60006250D1 DE60006250D1 DE60006250T DE60006250T DE60006250D1 DE 60006250 D1 DE60006250 D1 DE 60006250D1 DE 60006250 T DE60006250 T DE 60006250T DE 60006250 T DE60006250 T DE 60006250T DE 60006250 D1 DE60006250 D1 DE 60006250D1
- Authority
- DE
- Germany
- Prior art keywords
- peptides
- formula
- delayed release
- delayed
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14964999P | 1999-08-18 | 1999-08-18 | |
US149649P | 1999-08-18 | ||
PCT/US2000/022464 WO2001012233A2 (en) | 1999-08-18 | 2000-08-16 | Sustained release formulation of a peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60006250D1 true DE60006250D1 (de) | 2003-12-04 |
DE60006250T2 DE60006250T2 (de) | 2004-07-29 |
Family
ID=22531239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60027334T Expired - Lifetime DE60027334T2 (de) | 1999-08-18 | 2000-08-16 | Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist |
DE60006250T Expired - Lifetime DE60006250T2 (de) | 1999-08-18 | 2000-08-16 | Formulierung zur verzögerten freisetzung von peptiden |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60027334T Expired - Lifetime DE60027334T2 (de) | 1999-08-18 | 2000-08-16 | Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1204429B1 (de) |
JP (2) | JP4303438B2 (de) |
KR (1) | KR20020031407A (de) |
CN (1) | CN1164334C (de) |
AR (1) | AR025307A1 (de) |
AT (2) | ATE252915T1 (de) |
AU (1) | AU767837B2 (de) |
CA (1) | CA2391333C (de) |
CZ (1) | CZ2002333A3 (de) |
DE (2) | DE60027334T2 (de) |
DK (1) | DK1204429T3 (de) |
ES (2) | ES2209948T3 (de) |
HK (1) | HK1043308B (de) |
HU (1) | HUP0203060A3 (de) |
IL (1) | IL147802A0 (de) |
MX (1) | MXPA02001699A (de) |
NO (1) | NO20020771L (de) |
NZ (2) | NZ526127A (de) |
PL (1) | PL354120A1 (de) |
PT (1) | PT1204429E (de) |
RU (1) | RU2237675C2 (de) |
WO (1) | WO2001012233A2 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004200688B2 (en) * | 1999-08-18 | 2007-01-25 | Ipsen Pharma S.A.S. | Sustained release formulation of a peptide |
IES990700A2 (en) * | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
MXPA05008097A (es) | 2003-01-28 | 2006-02-08 | Microbia Inc | Metodos y composiciones para el tratamiento de desordenes gastrointestinales. |
PL1682537T3 (pl) | 2003-11-05 | 2012-09-28 | Sarcode Bioscience Inc | Modulatory adhezji komórkowej |
MY158342A (en) | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
LT2444079T (lt) | 2005-05-17 | 2017-03-27 | Sarcode Bioscience Inc. | Kompozicijos ir būdai, skirti akių sutrikimų gydymui |
EP2029625A2 (de) * | 2006-06-05 | 2009-03-04 | Novartis AG | Verwendung von tgf-beta-antagonisten bei der behandlung von parathyroid-vermittelten erkrankungen |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
EP2527360B1 (de) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase |
US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US9453020B2 (en) | 2011-05-04 | 2016-09-27 | Balance Therapeutics, Inc. | Substituted pentylenetetrazoles as GABA receptor activity modulators |
EP3715345B8 (de) | 2012-07-25 | 2024-05-29 | Bausch + Lomb Ireland Limited | Herstellung eines lfa-1-hemmers |
JP6499591B2 (ja) | 2013-02-25 | 2019-04-10 | シナジー ファーマシューティカルズ インコーポレイテッド | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP6661531B2 (ja) | 2013-10-10 | 2020-03-11 | シナジー ファーマシューティカルズ インコーポレイテッド | オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト |
WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
WO2017123634A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
RU2146128C1 (ru) * | 1993-01-06 | 2000-03-10 | Кинертон Лимитед | Ионный конъюгат с длительным периодом высвобождения пептида, способ синтезирования ионного конъюгата, способ синтезирования микрочастиц |
CN1055700C (zh) * | 1993-08-09 | 2000-08-23 | 生物测量公司 | 治疗用肽衍生物 |
IE960308A1 (en) * | 1996-04-23 | 1997-11-05 | Kinerton Ltd | Sustained release ionic conjugate |
PL329598A1 (en) * | 1996-04-23 | 1999-03-29 | Kinerton Ltd | Acidic lactic acid polymers |
AR020650A1 (es) * | 1998-08-10 | 2002-05-22 | Poly Med Inc | Polimeros fosforilados y conjugados de los mismos |
IES990700A2 (en) * | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
-
2000
- 2000-08-16 KR KR1020027001919A patent/KR20020031407A/ko not_active Application Discontinuation
- 2000-08-16 EP EP00954105A patent/EP1204429B1/de not_active Expired - Lifetime
- 2000-08-16 DE DE60027334T patent/DE60027334T2/de not_active Expired - Lifetime
- 2000-08-16 ES ES00954105T patent/ES2209948T3/es not_active Expired - Lifetime
- 2000-08-16 DK DK00954105T patent/DK1204429T3/da active
- 2000-08-16 HU HU0203060A patent/HUP0203060A3/hu unknown
- 2000-08-16 DE DE60006250T patent/DE60006250T2/de not_active Expired - Lifetime
- 2000-08-16 CN CNB008114943A patent/CN1164334C/zh not_active Expired - Fee Related
- 2000-08-16 AT AT00954105T patent/ATE252915T1/de not_active IP Right Cessation
- 2000-08-16 IL IL14780200A patent/IL147802A0/xx unknown
- 2000-08-16 PL PL00354120A patent/PL354120A1/xx not_active Application Discontinuation
- 2000-08-16 CZ CZ2002333A patent/CZ2002333A3/cs unknown
- 2000-08-16 ES ES03076829T patent/ES2258204T3/es not_active Expired - Lifetime
- 2000-08-16 RU RU2002106820A patent/RU2237675C2/ru not_active IP Right Cessation
- 2000-08-16 PT PT00954105T patent/PT1204429E/pt unknown
- 2000-08-16 MX MXPA02001699A patent/MXPA02001699A/es active IP Right Grant
- 2000-08-16 NZ NZ526127A patent/NZ526127A/en unknown
- 2000-08-16 CA CA002391333A patent/CA2391333C/en not_active Expired - Fee Related
- 2000-08-16 AU AU66444/00A patent/AU767837B2/en not_active Ceased
- 2000-08-16 WO PCT/US2000/022464 patent/WO2001012233A2/en not_active Application Discontinuation
- 2000-08-16 AT AT03076829T patent/ATE322911T1/de not_active IP Right Cessation
- 2000-08-16 JP JP2001516576A patent/JP4303438B2/ja not_active Expired - Fee Related
- 2000-08-16 NZ NZ517646A patent/NZ517646A/en unknown
- 2000-08-17 AR ARP000104253A patent/AR025307A1/es unknown
-
2002
- 2002-02-15 NO NO20020771A patent/NO20020771L/no unknown
- 2002-06-25 HK HK02104716.3A patent/HK1043308B/zh not_active IP Right Cessation
-
2005
- 2005-08-22 JP JP2005239282A patent/JP2006008701A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60006250D1 (de) | Formulierung zur verzögerten freisetzung von peptiden | |
AP2001002301A0 (en) | Inhibition of viral infection using monovalentantigen-binding proteins | |
DE60042550D1 (de) | Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i) | |
DE60025010D1 (de) | Chirurgisches system zur befestigung von gewebe | |
PT1210113E (pt) | Composicoes de vacinas de combinacao | |
ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
DE50004965D1 (de) | Inhibitorkomposition zur Stabilisierung von radikalisch polymerisierbaren Substanzen | |
EE200100649A (et) | A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks | |
AR027907A1 (es) | Composicion de liberacion controlada | |
FR2796072B1 (fr) | Peptides anti-microbiens de mollusques | |
ATE339438T1 (de) | Substanziell kristalline form von melagatran | |
NO20023445L (no) | Fremgangsmåte for fremstilling av peptider | |
DE60040524D1 (de) | Intein-vermittelte ligation von exprimierten proteinen | |
ATE253578T1 (de) | Oxazinochinolone zur behandlung von viralen infektionen | |
DE60039965D1 (de) | Zusammensetzung zur erwerbung von immunologischer toleranz | |
FR2794495B1 (fr) | Demarreur | |
FR2791348B1 (fr) | POLYPEPTIDE Npt2B | |
DE60012683D1 (de) | System zur Korrektur des Verwackelns | |
EP1246635A4 (de) | Conotoxin-peptide der o-superfamilie | |
FR2794178B1 (fr) | Demarreur | |
FR2794177B1 (fr) | Demarreur | |
DE69930733D1 (de) | Herstellung von substituierten (amino)alkoxysilanen | |
DE69830156D1 (de) | Zusammensetzungen zur immunverstärkung von impfstoffen | |
NO20013933D0 (no) | Peptider | |
ATE299704T1 (de) | Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: IPSEN PHARMA S.A.S., BOULOGNE-BILLANCOURT, FR |